KALA BIO, Inc. (KALA) is a Healthcare stock trading at $0.82 (as of 2026-08-21), with a market capitalization of $15.24M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Understand KALA BIO, Inc.: how it makes money
KALA BIO is a healthcare company focused on pharmaceutical products, and it makes money through selling pharmaceutical products.
With operating margin -2435%, the company currently runs a heavily loss-making profit model, so profitability depends on achieving substantial revenue growth and/or cost reductions.
Business quality (Unprofitable): Unprofitable, with operating margin -2435%.
Bull case
Scale could swing profitability: The company is loss-making, with operating margin -2435%, which implies high operating costs relative to revenue. If revenue grows meaningfully while costs do not rise as fast, profitability could improve quickly.
Bear case
Severe operating cost overhang: Operating margin -2435% signals that the current cost structure overwhelms the revenue base, making it difficult to generate operating profits in the near term.
Valuation — source: SEC EDGAR (first-party)
Price
$0.82
Market Cap
$15.24M
Price / Book
1.42
Price / Sales
12.56
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)
$0.00
Revenue Growth (YoY)
-84.0%
EPS Growth (YoY)
-90.1%
Financial Health — source: SEC EDGAR
Altman Z-Score
68.12 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)
21.7
Industry P/E (Pharmaceutical Products)
17.2
Company
Sector
Healthcare
Industry
Pharmaceutical Products
Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)